Hi 

MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio’s proprietary titratable form of LSD for take-home Microdosing). To date, nineteen out of twenty participants have started their dosing regimen and eight participants have successfully completed their entire treatment.

Click Here! To View Message

Justin Hanka, Chief Executive Officer of MindBio discusses the progress of two Phase 2 clinical trials currently underway and the expectation of a Q1 Phase 2A depression trial readout ahead of a large Phase 2B depression trial.

I'd like to wish everyone a Merry Christmas. Happy New Year. However, you choose to celebrate the end of the calendar year. I want to thank all our investors, shareholders and backers, supporters, advisors, and everyone who's getting behind us in this important work.

So Merry Christmas and Happy New Year to everyone. And we will see you in 2024. Stay tuned for updates in the new year.

JUSTIN HANKA

Co-founder

MindBio Therapeutics Corp

CSE:MBIO

Follow Justin Hanka on

LinkedIn: 

https://www.linkedin.com/in/justinhanka/

To learn more about MindBio go here

https://www.mindbiotherapeutics.com/